Log in to search using one of your social media accounts:

 

Geographic Outcomes of Metastatic RCC in Canada & Europe ESMO-MCBS shows real world data of the availability of new drugs
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Geographic Outcomes of Metastatic RCC in Canada & Europe ESMO-MCBS shows real world data of the availability of new drugs at Kidney Cancer ... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2018 Category: Cancer & Oncology Source Type: podcasts

Impact of Geographic Region in Clinical Outcome of Metastatic RCC The overall & progression-free survival seem similar across geographic regions
Andr P Fay, MD Hospital Me De Deus Cancer Institute, discusses Impact of Geographic Region in Clinical Outcome of Metastatic RCC The overall & progression-free survival seem similar across geographi... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2018 Category: Cancer & Oncology Source Type: podcasts

Many VEGF Phase 3 Trials Have Completed Accrual Colleagues can visit clinicaltrials.gov to see which are currently accruing
Tian Zhang, MD Duke University Medical Center, discusses Many VEGF Phase 3 Trials Have Completed Accrual Colleagues can visit clinicaltrials.gov to see which are currently accruing at Kidney Cancer A... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Physician-Directed Patient-Oriented Improvements How physicians can deliver the best care & cost-intensive but still deliver value
Robert Uzzo, MD Fox Chase Cancer Center, discusses Physician-Directed Patient-Oriented Improvements How physicians can deliver the best care & cost-intensive but still deliver value at Kidney Cancer A... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Canada Negotiates Drug Prices w Pan-Canadian Consortium Sunitinib & Pazopanib are most commonly prescribed off trial settings
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Canada Negotiates Drug Prices w Pan-Canadian Consortium Sunitinib & Pazopanib are most commonly prescribed off trial settings at Kidney Can... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Economic Research and Value in Kidney Cancer Value incentivizes provider & delivery of high value quality-based care
Robert Uzzo, MD Fox Chase Cancer Center, discusses Economic Research and Value in Kidney Cancer Value incentivizes provider & delivery of high value quality-based care at Kidney Cancer Association 201... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival at Kidney Cancer Association 201... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Patient Power Message to OncologyTube Viewers
For years, Patient Power has made its rich library of video content for people living with cancer and their loved ones available on OncologyTube.com. Now, so that you can access all the features and s... Author: patientpower Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Transforming Care After Treatment (TCAT): technology in the delivery of supportive care to lung cancer patients
Following cancer treatment, it is important to support and enable an increasing number of cancer survivors to live as healthy a life as possible for as long as possible. In this interview, Pamela Rose... Author: VJOncology Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Next steps for an innovative electronic holistic care needs assessment tool in Scotland for cancer patients
Following the promising results of initial investigations into the use of an electronic healthcare assessment tool in the delivery of supportive care to lung cancer patients, the tool is going to cont... Author: VJOncology Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Technology in the supportive care of lung cancer patients: patient preference and impact on time efficiency
Integrating technology into healthcare service delivery can improve patient experience whilst improving efficiency. In this interview, Pamela Rose, Macmillan Lung Cancer Clinical Nurse Specialist, of ... Author: VJOncology Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

An information film to promote informed decision-making for a lung cancer screening
As lung cancer screening is a relatively new area, particularly to non-healthcare professionals, understanding of the procedure and risks involved are generally not well understood. Here, Mamta Rupare... Author: VJOncology Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Nurses and recognizing each others work pressures
Staff within the NHS are very busy and work pressures can result in less time for communication between nurses. In this interview, Anne Croudass, Lead Research Nurse at Cancer Research UK (CRUK), Lond... Author: VJOncology Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

The nurses role in improving the clinical trial experience of patients
What can be done to improve the experience of clinical trials for patients who participate? In this interview, recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverp... Author: VJOncology Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Meeting in the box: working out the best practice strategies for HCPs and patients
Different NHS trusts work in different ways; what could be considered the best practice in one trust may not be practical in another. In this interview, recorded at the 2017 National Cancer Research I... Author: VJOncology Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

New therapeutic targets in CLL: ROR1
The identification of novel therapeutic targets is essential for the improved treatment of hematological cancer, particularly due to the development of drug resistance. Here, Constantine Tam, MD, FRAC... Author: VJHemOnc Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Pembrolizumab: defining standards of care in urothelial cancer
Following the completion of the initial stages of the KEYNOTE-045 trial of pembrolizumab vs. the standard care for advanced urothelial cancer following chemotherapy (NCT02256436), clinicians have been... Author: VJOncology Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

TKI and checkpoint inhibitor combinations for kidney cancer: the IMmotion151 trial
The current standard of care for frontline kidney cancer is tyrosine kinase inhibitor (TKI) treatment. Now there are a host of promising immune checkpoint inhibitors in trials for this indication, eit... Author: VJOncology Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Promising POUT: perioperative chemotherapy for upper tract urothelial cancer
The UK was well represented at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. In this video, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer... Author: VJOncology Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

What does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
Long-term follow-up data is the real determinant of the efficacy of novel therapies. Here, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, di... Author: VJOncology Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic CRPC
The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the sequencing and uses of enzalutamide are bei... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Differentiating aggressive vs. non-aggressive prostate cancer: the MiCheck GPC1 biomarker test
The addition of a new prostate cancer diagnostic test to inform clinicians and patients prior to the decision to biopsy would be beneficial, in conjunction with the traditional measures of PSA and DRE... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

How will new NSAAs impact clinical practice in prostate cancer?
Previously, patients with nonmetastatic castration-resistant prostate cancer (nmCRPRC) and the clinicians treating them had no therapeutic options to delay disease progression. Now there are two new n... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Live long and PROSPER: enzalutamide for nmCRPC
There has previously been no approved treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC), due to a lack of evidence that any drug would prevent disease progression in this popul... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunothera... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses tUsing Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements at... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients at the 2018 ASCO. Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Overlooked Biomarker May Predict Cancer Immunotherapy Response
Dr David Kerr on data showing that tumors with extensive aneuploidy may not benefit as much from immune checkpoint blockade. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+ disease can be pushed even further. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

"We don't really know the impact of these products on our health": Ultraprocessed food & cancer risk
A study published by The BMJ today reports a possible association between intake of highly processed ( “ultra-processed”) food in the diet and cancer. Ultra-processed foods include packaged baked goods and snacks, fizzy drinks, sugary cereals, ready meals and reconstituted meat products - often containing high levels of sugar, fat, and salt, but... (Source: The BMJ Podcast)
Source: The BMJ Podcast - February 15, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Obesity's Impact on Screening for Cervical Cancer
Dr Andrew Kaunitz highlights an important study, with implications for vaginal examination and cervical cancer screening in obese women. (Source: Medscape ObGyn Podcast)
Source: Medscape ObGyn Podcast - February 14, 2018 Category: OBGYN Authors: Medscape Source Type: podcasts

MABp1: 'Clever' New Antibody Targeting Colorectal Cancer
A trial using MABp1, an antibody targeting interleukin 1 alpha, showed some benefit for patients with advanced colorectal cancer, but Dr Kerr thinks the clinical endpoint used was a'little soft.'(Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - February 14, 2018 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

Excluding PE in Low-Risk ED Patients, Screening for Ovarian Cancer, COIs in Nutrition Research, and more
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the February 13, 2018 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - February 13, 2018 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts

USPSTF Recommendation: Screening for Ovarian Cancer
Interview with Michael J. Barry, MD, Task Force member and co-author of Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - February 13, 2018 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

An MRI-based approach to prostate cancer diagnosis: a urologists stance in the debate
The first study illustrating the potential of MRI in the diagnosis of prostate cancer was published in 2006. Although there have since been a number of other studies showing this utility, the use of M... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Challenges for prostate cancer: overdiagnosis and unnecessary treatment
The current diagnostic methods for prostate cancer are not always as reliable or accurate as they could be, leading to mis- or over-diagnosis, and thus the treatment of patients who will not benefit f... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Is delayed diagnosis in the UK to blame for poorer cancer outcomes?
Recent news reports have identified poorer outcomes in cancer patients from the UK compared with those in certain other European countries. Here, Mark Emberton, MD, FRCS, of University College London,... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

MRI-based prostate cancer diagnosis: economic and logistical considerations
The take-home message from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, on MRI for prostate cancer diagnosis was positive. However, this leaves us with a variety of questions. In th... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

MRI and MRI-directed biopsies for the diagnosis of prostate cancer
The utilization of MRI for the diagnosis of prostate cancer in men at risk is relatively new. In this interview, filmed at the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, Mark Emberton... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Teamwork between urologists and oncologists in the UK
Current practice in the UK requires urologists to refer patients with urological cancer to oncologists for treatment. In this interview, Mark Emberton, MD, FRCS, of University College London, London, ... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

This is SPARTAN! Apalutamide treatment for nmCRPC
Highly anticipated data from the Phase III SPARTAN study (NCT01946204), which investigated apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC), was presented at the 2018 Genito... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Straightforward study design: SPARTAN trial of apalutamide for nmCRPC
There has previously been no effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC). Now there are several exciting late-phase clinical trials investigating promising trea... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

How will the results of the SPARTAN study impact US clinical practice in prostate cancer?
The emergence of an effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is likely to have a paradigm-changing effect on the treatment of CRPC. In this informative talk ... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

Nonmetastatic CRPC: meeting an unmet need
Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a disease which had no FDA-approved treatment. Following the completion of the Phase III SPARTAN trial (NCT01946204), a new nonsteroidal ... Author: VJOncology Added: 02/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 12, 2018 Category: Cancer & Oncology Source Type: podcasts

PD-L1 and TMB as biomarkers in the IMvigor211 trial of atezolizumab vs. chemo for bladder cancer
A highly anticipated topic at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, was immune checkpoint inhibitor data for bladder cancer. Here, Thomas Powles, MD, of Barts Cancer Ins... Author: VJOncology Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
Immune checkpoint inhibitors for urothelial carcinoma in the relapsed/refractory setting have already been approved and are superseding standard chemotherapy. Now, there are exciting late-phase clinic... Author: VJOncology Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Immune checkpoint inhibitors for urothelial carcinoma: the current landscape
Novel immune checkpoint inhibitors that are entering the clinic are changing the way in which we treat metastatic urothelial carcinoma, the most common type of bladder cancer. In this interview, Thoma... Author: VJOncology Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Triple therapy including nivolumab for newly diagnosed AML
Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the pilot Phase II study (NCT02464657) of cytarabine, idarubicin and the PD-1 inhibitor... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

IDEA Trial Remakes Adjuvant Chemo in Colorectal Cancer
Dr David Kerr on how one of the biggest studies at ASCO is already changing practice. (Source: Medscape Oncology)
Source: Medscape Oncology - February 9, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts